Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [2]. Core Insights - The company has entered a value realization phase with its AI pharmaceutical platform, highlighted by the clinical trial approval of its drug RTX-117 for Charcot-Marie-Tooth disease, marking a significant milestone in its drug development pipeline [6]. - The innovative approach of RTX-117 targets the key mechanisms of the disease, demonstrating effective restoration of motor function in preclinical studies, thus validating the company's AI-driven drug development capabilities [6]. - The company has established a robust business model that integrates AI technology with a flexible commercial strategy, allowing for rapid drug development and a diversified revenue stream from collaborations with major pharmaceutical companies [6]. - The financial projections indicate substantial revenue growth, with expected revenues of RMB 785 million in 2025 and RMB 1.485 billion in 2027, alongside a path to profitability by 2027 [2][7]. Financial Projections - Revenue is projected to grow from RMB 266 million in 2024 to RMB 1.485 billion in 2027, reflecting a compound annual growth rate (CAGR) of approximately 36.6% [2][7]. - The net profit attributable to shareholders is expected to improve from a loss of RMB 1.517 billion in 2024 to a profit of RMB 92 million in 2027, indicating a significant turnaround [2][7]. - The earnings per share (EPS) is forecasted to transition from -0.35 RMB in 2024 to 0.02 RMB in 2027, suggesting a positive shift towards profitability [2][7].

Core Insights - On January 13, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 81.05 billion, 29.45 billion, and 28.57 billion respectively [1] - The same companies also led in trading volume in the Shenzhen-Hong Kong Stock Connect, with trading amounts of 58.01 billion, 23.48 billion, and 21.05 billion respectively [1] Southbound Stock Connect (Shanghai-Hong Kong) - Alibaba-W (09988) had a trading amount of 81.05 billion and a net buy amount of -90.46 million [2] - Tencent Holdings (00700) recorded a trading amount of 29.45 billion with a net buy amount of +6.61 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 28.57 billion and a net buy amount of +3.24 billion [2] - Other notable companies included Goldwind Technology (02208) with 23.07 billion and a net buy of +85.70 million, and SMIC (00981) with 22.72 billion and a net buy of -1.73 billion [2] Southbound Stock Connect (Shenzhen-Hong Kong) - Alibaba-W (09988) had a trading amount of 58.01 billion and a net buy amount of +1.16 billion [2] - Tencent Holdings (00700) recorded a trading amount of 23.48 billion with a net buy amount of +749 million [2] - Xiaomi Group-W (01810) achieved a trading amount of 21.05 billion and a net buy amount of +283 million [2] - Other significant companies included SMIC (00981) with 18.13 billion and a net buy of -661 million, and Kuaishou-W (01024) with 12.21 billion and a net buy of +114 million [2]

Core Viewpoint - The AI healthcare concept stocks experienced significant gains in the afternoon trading session, indicating a positive market sentiment towards this sector [1][4]. Stock Performance Summary - Ark Health (06086) saw a remarkable increase of 52.74%, rising by 3.62 HKD [1][4]. - Crystal Tech Holdings (02228) rose by 5.17%, reaching a price of 13.62 HKD [1][4]. - Yimaitong (02192) increased by 4.94%, with a current price of 13.80 HKD [1][4]. - Alibaba Health (00241) experienced a gain of 2.52%, trading at 6.52 HKD [1][4]. - iFlytek Medical Technology (02506) saw a modest increase of 1.30%, priced at 109.10 HKD [1][4].

Group 1 - The core viewpoint of the news is that AI healthcare concept stocks are experiencing significant gains, driven by a partnership between Nvidia and Eli Lilly to invest $1 billion in a joint research lab to accelerate AI applications in the pharmaceutical industry [1][2] - Ark Health (06086) saw a rise of 30.8%, while other AI healthcare stocks like Medical Pulse (02192) and Crystal Technology Holdings (02228) also reported increases of 5.1% and 4.63% respectively [1] - The joint lab established by Nvidia and Eli Lilly aims to generate large-scale data and build AI models to enhance new drug development, with operations expected to start early this year [1] Group 2 - According to Fengzheng Securities, AI-driven healthcare is forming a new growth engine, with a positive outlook on the revolutionary potential of AI in pharmaceuticals, basic research, diagnosis, and health management [2] - Huafu Securities noted that the AI healthcare industry has entered a critical stage of commercialization, supported by national strategies and market demand, with a closed-loop demand for AI applications sustaining the sustainable development of the AI industry [2]

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 客户端 晶泰控股（02228）早盘涨超6%，本月内累计涨幅已超40%。截至发稿，股价上涨6.87%，报13.84港 元，成交额12.47亿港元。 1月7日，晶泰科技宣布孵化企业ReviR溪砾科技的小分子药物RTX-117获得国家药监局临床试验批准， 计划于1Q 2026启动I期临床。该管线为国内首款针对腓骨肌萎缩症（CMT）的1类创新药，也是ReviR 与晶泰科技合作借助AI+机器人辅助研发的一系列罕见病药物管线中首个进入临床的项目。 晶泰控股（02228）早盘涨超6%，本月内累计涨幅已超40%。截至发稿，股价上涨6.87%，报13.84港 元，成交额12.47亿港元。 1月7日，晶泰科技宣布孵化企业ReviR溪砾科技的小分子药物RTX-117获得国家药监局临床试验批准， 计划于1Q 2026启动I期临床。该管线为国内首款针对腓骨肌萎缩症（CMT）的1类创新药，也是ReviR 与晶泰科技合作借助AI+机器人辅助研发的一系列罕见病药物管线中首个进入临床的项目。 国联民生证券发布研报称，晶泰控股在AI制药领域的软硬件技术沉淀、平台化商业模式及关键赛 ...

每经AI快讯，晶泰控股(02228.HK)涨超6%。截至发稿，晶泰控股涨6.18%，报13.75港元，成交额8.19亿 港元。 ...

Core Viewpoint - Jingtai Holdings (02228) has seen its stock price increase by over 40% in January, with a current rise of 6.18% to HKD 13.75, and a trading volume of HKD 819 million [1] Group 1: Company Developments - Jingtai Technology announced that its incubated company, ReviR Technology, received clinical trial approval from the National Medical Products Administration for its small molecule drug RTX-117, which is set to begin Phase I clinical trials in Q1 2026 [1] - RTX-117 is the first innovative drug in China targeting Charcot-Marie-Tooth disease (CMT) and is the first project to enter clinical trials from a series of rare disease drug pipelines developed in collaboration with AI and robotics [1] Group 2: Market Analysis - Guolian Minsheng Securities released a report stating that Jingtai Holdings has established a competitive edge in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and key market positioning [1] - The approval of RTX-117 for clinical trials marks the beginning of the value realization phase for its technology platform, with significant potential for performance elasticity and valuation restructuring as the pipeline continues to expand [1]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant increase in stock price, rising over 40% in the month, with a current price of HKD 13.75 and a trading volume of HKD 819 million [1] Group 1: Company Developments - On January 7, Jingtai Technology announced that its incubated company, ReviR Technology, received clinical trial approval from the National Medical Products Administration for its small molecule drug RTX-117, which is set to begin Phase I clinical trials in Q1 2026 [1] - RTX-117 is the first Class I innovative drug targeting Charcot-Marie-Tooth disease (CMT) in China and is the first project to enter clinical trials from a series of rare disease drug pipelines developed through AI and robotic-assisted research in collaboration with ReviR [1] Group 2: Market Analysis - Guolian Minsheng Securities (601456) released a report stating that Jingtai Holdings has established a competitive edge in the AI pharmaceutical sector through its software and hardware technology accumulation, platform-based business model, and strategic positioning in key market segments [1] - The approval of RTX-117 for clinical trials marks the beginning of the value realization phase for its technology platform, with expectations for continued expansion of collaborative pipelines, leading to significant performance elasticity and valuation reconfiguration potential [1]

Summary of Key Points from the Conference Call Company Overview - **Company**: 京泰控股 (JingTai Holdings) - **Industry**: AI in Pharmaceutical Development Core Insights and Arguments - **AI in Pharmaceutical Development**: The AI pharmaceutical sector is gaining attention due to high data barriers, the need for industry expertise, and significant scalability potential. The aging population and global R&D investments provide ample growth opportunities in this sector [2][6]. - **Business Model**: 京泰控股 operates on a high upfront investment model, transitioning to stable long-term revenue through clinical and sales phases. Collaborations with DeepTree and Eli Lilly utilize upfront payments, milestone payments, and revenue sharing to smooth income fluctuations [2][8]. - **Technological Strength**: The company leverages quantum physics, AI, and robotics to offer R&D solutions, having signed a $6 billion contract with DeepTree and partnered with major pharmaceutical companies like Johnson & Johnson and Pfizer, validating its technological capabilities [2][7]. - **Product Development**: The company’s subsidiary, 西力科技 (XiLi Technology), has received FDA approval for RNA small molecule innovative drugs and orphan drug designation, with small molecule and peptide hair growth products also approved for overseas sales, indicating strong market potential [2][9]. Market Dynamics - **Hair Loss Treatment Market**: The Chinese hair loss treatment market is projected to grow from 500 million yuan in 2018 to 3.5 billion yuan by 2024, with a compound annual growth rate (CAGR) of approximately 40%. The leading company, 曼迪国际 (Mandi International), is expected to achieve revenues of 1.455 billion yuan in 2024, reflecting an 18.5% year-on-year growth and a gross margin of 82.7% [2][10]. - **Mandi International's Product Advantages**: Mandi's minoxidil series products are noted for their rapid efficacy, significant results, and high safety profile, with a monthly overseas price of 389 yuan. The company aims to expand sales from B2B to B2C markets [2][11]. Strategic Collaborations - **Partnership with 晶科能源 (Jinko Solar)**: 京泰控股 has formed a strategic partnership with Jinko Solar to establish an AI-driven battery manufacturing line, which will also extend into solar photovoltaic applications, creating new profit growth points and a data flywheel effect [2][12]. Financial Projections - **Revenue and Profit Forecast**: The company anticipates revenues of 787 million yuan, 998 million yuan, and 1.465 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 195.3%, 26.8%, and 46.7%. The net profit is expected to transition from losses to profitability, indicating a rapid performance release phase [2][13]. Technological and Market Position - **Technological Capabilities**: 京泰控股's quantum physics technology is applicable in drug discovery and chemical raw materials, positioning the company as a key player in the AI for Science infrastructure. The company aims to enhance R&D efficiency and establish close collaborations with pharmaceutical companies while minimizing risks [2][14][15]. - **AI Medical Sector Trends**: The rapid development of the AI medical sector, exemplified by companies like TEMPUS, is expected to lead to valuation shifts and commercial model validations, positively impacting 京泰控股's growth prospects [2][16].

Market Overview - On January 12, the Hang Seng Index rose by 1.44%, with total southbound trading amounting to HKD 1,474.94 billion, including buy transactions of HKD 774.00 billion and sell transactions of HKD 700.94 billion, resulting in a net buy of HKD 73.06 billion [2][3]. Southbound Trading Details - The southbound trading through Stock Connect (Shenzhen) had a total transaction amount of HKD 610.81 billion, with buy transactions of HKD 334.20 billion and sell transactions of HKD 276.61 billion, leading to a net buy of HKD 57.60 billion [2]. - The southbound trading through Stock Connect (Shanghai) had a total transaction amount of HKD 864.13 billion, with buy transactions of HKD 439.80 billion and sell transactions of HKD 424.33 billion, resulting in a net buy of HKD 15.46 billion [2]. Active Stocks - The most actively traded stock by southbound funds was Alibaba-W, with a total transaction amount of HKD 156.07 billion, followed by Tencent Holdings and Xiaomi Group-W, with transaction amounts of HKD 70.06 billion and HKD 46.71 billion, respectively [2][3]. - Among the net buying stocks, Kuaishou-W had the highest net buy amount of HKD 22.45 billion, with a closing price increase of 7.43%. Tencent Holdings followed with a net buy of HKD 20.12 billion, and Southern Hang Seng Technology had a net buy of HKD 8.58 billion [2][3]. Continuous Net Buying and Selling - Three stocks experienced continuous net buying for more than three days, with Xiaomi Group-W leading at 8 days, followed by Tencent Holdings at 4 days and SMIC at 3 days. The total net buy amounts were HKD 63.26 billion for Xiaomi Group-W, HKD 62.43 billion for Tencent Holdings, and HKD 12.79 billion for SMIC [3]. - Two stocks faced continuous net selling, with China Mobile and Meituan-W having the highest net sell amounts of HKD 44.80 billion and HKD 10.76 billion, respectively [3].